Editas-Logo-Small (1).jpg
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
February 16, 2018 09:00 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of...
Editas-Logo-Small (1).jpg
Editas Medicine to Participate in Upcoming Investor Conferences
February 08, 2018 16:01 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor...
Editas-Logo-Small (1).jpg
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
January 08, 2018 09:00 ET | Editas Medicine, Inc.
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first...
Editas-Logo-Small (1).jpg
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 08:57 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas-Logo-Small (1).jpg
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
December 11, 2017 18:00 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Third Quarter 2017 Results and Update
November 07, 2017 16:03 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30,...
Editas-Logo-Small (1).jpg
Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
November 03, 2017 08:00 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas-Logo-Small (1).jpg
Editas Medicine to Participate in Investor Conferences in October
October 03, 2017 08:00 ET | Editas Medicine
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas-Logo-Small (1).jpg
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
September 12, 2017 08:00 ET | Editas Medicine
CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history...
Editas-Logo-Small (1).jpg
Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
September 05, 2017 08:00 ET | Editas Medicine
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the...